101 related articles for article (PubMed ID: 22196975)
1. A comparative assessment of α-lipoic acid N-phenylamides as non-steroidal androgen receptor antagonists both on and off gold nanoparticles.
Henderson LC; Altimari JM; Dyson G; Servinis L; Niranjan B; Risbridger GP
Bioorg Chem; 2012 Feb; 40(1):1-5. PubMed ID: 22196975
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor antagonists and anti-prostate cancer activities of some synthesized steroidal candidates.
Bahashwan SA; Al-Omar MA; Ezzeldin E; Abdalla MM; Fayed AA; Amr AG
Chem Pharm Bull (Tokyo); 2011; 59(11):1363-8. PubMed ID: 22041072
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
5. Circumventing anti-androgen resistance by molecular design.
McGinley PL; Koh JT
J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
[TBL] [Abstract][Full Text] [Related]
6. Developments in nonsteroidal antiandrogens targeting the androgen receptor.
Liu B; Su L; Geng J; Liu J; Zhao G
ChemMedChem; 2010 Oct; 5(10):1651-61. PubMed ID: 20853390
[No Abstract] [Full Text] [Related]
7. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
8. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
[TBL] [Abstract][Full Text] [Related]
10. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
11. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
12. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
13. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
[TBL] [Abstract][Full Text] [Related]
14. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
17. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
18. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
Liu H; Han R; Li J; Liu H; Zheng L
J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]